Carnegie acted as sole manager and financial adviser in the fully underwritten SEK 406 million rights issue in PledPharma. PledPharma is a Swedish pharmaceutical company developing new drugs that protect the body against oxidative stress – a potentially disabling and sometimes life-threatening condition that can be caused by chemotherapy and acetaminophen poisoning. December 2016.
Healthcare
Rights issue in PledPharma (SE) — SEK 406 million
December 2016